Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Nov 17, 2021

Accession no.
0001447362-21-000259
Filed
Nov 17, 2021
Trade date
Nov 15-16, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $861.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2021Common StockMOption exerciseAcquired+16,406$2.36+$38,718.16302,424Direct
Nov 15, 2021Common StockSSaleDisposed−15,394$52.47F1−$807,723.18287,030Direct
Nov 15, 2021Common StockSSaleDisposed−1,012$53.04F2−$53,676.48286,018Direct
Nov 16, 2021Common StockMOption exerciseAcquired+15,409$3.72+$57,321.48301,427Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2021Common StockMOption exerciseDisposed−16,406$0.00$00Direct
Nov 16, 2021Common StockMOption exerciseDisposed−15,409$0.00$020,686Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed in multiple trades at prices ranging from $52.000 to $52.995, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F2

This transaction was executed in multiple trades at prices ranging from $53.000 to $53.170, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)